Comment: Management of Hypertension in Renal Transplant Patients: A Comprehensive Review of Nonpharmacologic and Pharmacologic Treatment Strategies

Dunn BL , Teusink AC , Taber DJ , Hemstreet BA , Uber LA , Weimert NA . Management of hypertension in renal transplant patients: a comprehensive review of nonpharmacologic and pharmacologic treatment strategies. Ann Pharmacother 2010; 44:1259–70. DOI 10.1345/aph.1P004

Baroletti SA , Gabardi S , Magee CC , Milford EL . Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction. Pharmacotherapy 2003; 23:788–801.

Cross NB , Webster AC , Masson P , O'Connell PJ , Craig JC . Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009; 88:7–18.

Cross NB , Webster AC , Masson P , O'Connell PJ , Craig JC . Antihypertensive treatment for kidney transplant recipients. Cochrane Database Syst Rev 2009: CD003598.

Tedla F , Hayashi R , McFarlane SI , Salifu MO . Hypertension after renal transplant. J Clin Hypertens (Greenwich) 2007; 9:538–45.

Castillo-Lugo JA , Vergne-Marini P . Hypertension in kidney transplantation. Semin Nephrol 2005; 25:252–60.

Park JM , Luan FL . Management of hypertension in solid-organ transplantation. Prog Transplant 2005; 15:17–22.

Persson F , Lewis JB , Lewis EJ , Rossing P , Hollenberg NK , Parving HH . Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care 2010; 33:2304–9.

Persson F , Rossing P , Reinhard H . Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia 2010; 53:1576–80.

Parving HH , Persson F , Lewis JB , Lewis EJ , Hollenberg NK . Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433–46.

Freiberger V , Amann K , Heemann U , Frank H . Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation. Transpl Int 2009; 22:1110–3.

Package insert. Tekturna (aliskiren). East Hanover, NJ: Novartis Pharmaceutical Corp, 2009.

Gandhi C , Zalawadia R , Balaraman R . Nebivolol reduces experimentally induced warm renal ischemia reperfusion injury in rats. Ren Fail 2008; 30:921–30.

van de Borne P , Fici F , Makel W , Fiasse A , Degaute J , Leeman M . The effect of nebivolol and atenolol on renal and systemic haemodynamics in hypertensive patients high blood pressure & cardiovascular prevention. High Blood Pres Cardiovasc Prev 2007; 14:133–7.

Georgescu A , Popov D , Dragan E , Dragomir E , Badila E . Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension. Eur J Pharmacol 2007; 570:149–58.

Tzemos N , Lim PO , MacDonald TM . Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001; 104:511–4.

Nebivolol effect on nitric oxide levels, blood pressure, and renal function in kidney transplant patients. http://clinicaltrials.gov/ct2/show/NCT01157234?term=nebivolol+and+renal+transplant&rank=1 (accessed 2010 Nov 23).

Package insert. Bystolic (nebivolol). St. Louis, MO: Forest Pharmaceuticals, Inc., 2008.

Macunluoglu B , Arikan H , Atakan A . Effects of spironolactone in an experimental model of chronic cyclosporine nephrotoxicity. Transplant Proc 2008; 40:273–8.

Waanders F , Rienstra H , Boer MW . Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats. Am J Physiol Renal Physiol 2009; 296:F1072–9.